The approval that changes prescription access, not grocery decisions
The Central Drugs Standard Control Organization has approved Novo Nordisk's Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis, a form of advanced fatty liver disease. This is a prescription drug for a narrow medical indication. It does not affect what households buy, cook, or plan.
Wegovy was previously approved for adolescent obesity in India in May 2024. This new approval expands the clinical situations in which physicians may prescribe the drug, but it does not expand household access to weight management tools or change the food strategy that addresses liver health and weight across the population.
What MASH is—and why most readers don't have it
MASH is advanced fatty liver disease characterized by inflammation and liver cell damage. It is diagnosed by a physician through clinical assessment, imaging, and sometimes biopsy. It is not self-identified by symptoms or weight status.
MASH represents a small subset of people with metabolic dysfunction. Having excess weight or eating a poor diet does not mean you have MASH. Most people with fatty liver have earlier stages of the condition that do not involve the inflammation and cell damage that define MASH. The disease exists on a spectrum, and the drug approval targets the advanced end of that spectrum.
What Wegovy is—and what this approval does not make available
Wegovy is semaglutide, a GLP-1 receptor agonist. It requires a prescription, physician assessment, and likely specialist referral. Approval does not mean affordability, insurance coverage, or widespread availability.
This is not a weight-loss product households can request or shop for. The regulatory decision expands the labeled indications for a prescription medication. It does not create a pathway for people concerned about weight or general liver health to access the drug. Pricing and reimbursement details have not been disclosed. The timeline for availability and the real-world prescribing patterns remain unclear.
Why fatty liver disease still requires the same food strategy
Fatty liver disease, including the early stages before MASH develops, responds to calorie reduction, weight loss, and limiting added sugar and alcohol. No drug approval changes that core dietary strategy.
Prescription drugs treat advanced disease. Food strategy addresses the spectrum. A household managing metabolic risk—whether or not anyone has been diagnosed with fatty liver disease—does so through what it buys and eats, not through drug access.
Reducing added sugar means choosing unsweetened beverages, reading labels on packaged foods, and limiting desserts and sweetened snacks. Limiting alcohol means fewer drinks per week or none at all. Calorie reduction, when weight loss is needed, means smaller portions, less cooking fat, and fewer energy-dense convenience foods. These actions apply regardless of drug availability.
What remains unknown about this approval
The public coverage of the approval does not detail the specific clinical criteria or patient profiles required for prescribing Wegovy for fatty liver disease in India. Patient eligibility criteria have not been made clear.
Pricing has not been announced. Reimbursement pathways are unknown. The availability timeline is unclear. How physicians will prescribe the drug, which patients will gain access, and what barriers will emerge in real-world practice are not yet visible.
If you're concerned about liver health or weight
Reduce added sugar and alcohol intake. Prioritize a calorie deficit if weight loss is needed. See a physician if you have metabolic risk factors—not to request this drug, but for assessment of liver health, blood sugar, and cardiovascular risk.
No grocery or meal decision hinges on this approval. The food strategy that reduces liver fat, improves metabolic health, and supports weight loss remains unchanged. Buy less sugar. Drink less alcohol. Eat fewer calories if you need to lose weight. Cook more meals from whole ingredients. These actions address the conditions that lead to fatty liver disease at every stage, including the advanced form now treatable with a prescription drug most households will never access.
Added sugar in common drinks and foods—daily intake context
Comparison basis: Typical single serving as consumed
| Food / drink | Added sugar per serving | Daily limit context | Better choice |
|---|---|---|---|
| Regular cola (330 ml can) | ~35 g (9 tsp) | Exceeds WHO daily limit alone | Unsweetened sparkling water |
| Sweetened iced tea (500 ml bottle) | ~25 g (6 tsp) | Over half daily limit | Unsweetened tea or water |
| Flavoured yogurt (150 g cup) | ~15 g (4 tsp) | One-third daily limit | Plain yogurt with fresh fruit |
| Breakfast cereal (40 g serving) | ~10 g (2.5 tsp) | One-fifth daily limit | Unsweetened oats or muesli |
| Packaged fruit juice (200 ml) | ~20 g (5 tsp) | Nearly half daily limit | Whole fruit with water |
| Chocolate biscuits (3 pieces) | ~12 g (3 tsp) | One-quarter daily limit | Plain crackers or nuts |
| Tomato ketchup (2 tbsp) | ~8 g (2 tsp) | One-sixth daily limit | Fresh tomato or plain chutney |
Values are approximate and vary by brand and recipe. WHO recommends limiting added sugar to under 50 g daily, ideally under 25 g. These amounts exclude naturally occurring sugars in whole fruit, plain milk, or vegetables.
Comments
No login needed. Keep it kind — abusive language is filtered.